NCT01354483

Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury

Feasibility and Safety of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: China Spinal Cord Injury Network · Network
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.

Detailed description

This is an open-label dose-escalating clinical trial. 20 patients will be randomly divided into 5 groups, 4 patient per group. The first three groups of four patients will receive transplants of increasing dose of HLA-matched umbilical cord blood mononuclear cells, starting from 4 spinal cord injection of 4µL of cell suspensions in Group A to 8µL in Group B and 16µL in Group C. If more than one subjects show neurological loss attributable to the cell injections, the trial will fall back to the previous dose. In the Group D, the highest volume of cells that do not cause neurological deficits (e.g. 16µL x4) along with a single bolus of 30 mg/kg methylprednisolone sodium succinate (MPSS) will be provided. Subjects in the Group E receive the same treatment as Group D plus a 6-week course of oral lithium carbonate. All subjects will enroll for three months intensive rehabilitation after the cell transplant.

Conditions

• Spinal Cord Injuries

Interventions

Type	Name	Description
BIOLOGICAL	Umbilical Cord Blood Mononuclear Cell
BIOLOGICAL	Methylprednisolone	30mg/kg i.v. methylprednisolone
DRUG	Lithium Carbonate Tablet	6 weeks

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-09-01
• Completion: 2013-12-01
• First posted: 2011-05-17
• Last updated: 2014-08-21

Locations

1 site across 1 country: China